Rucaparib (AG-014699) phosphate

Catalog No.S1098 Synonyms: PF-01367338

For research use only.

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Rucaparib (AG-014699) phosphate Chemical Structure

CAS No. 459868-92-9

Selleck's Rucaparib (AG-014699) phosphate has been cited by 111 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Other PARP Products

Biological Activity

Description Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Features The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
In vitro

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 M3HRfmZ2dmO2aX;uJGF{e2G7 NHvrbZIxNjFxMT:1NFAwOTByMDDuUS=> NU\hZWJzcW6qaXLpeJMhWEGUUDDhZ5Rqfmm2eTDheEB{fGG{dHnu[{Bkd26lZYLueJJifGmxbjDv[kA2ODBibl2= NVTlWlg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlg1PTVpPkK1NVI5PDV3PD;hQi=>
BT474 NUD2V2R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfTfo82ODBibl2= MoHSNVDjiJNzNdMg[C=> MoTZdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> M{\sTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
SKBR3 NEPKWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XuOVUxOCCwTR?= NFnSbnAyOOLCk{G1xsBl MknkdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> Mon0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
AU565 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomyOVAxKG6P NIT4RXQyOOLCk{G1xsBl NX75eIk5emWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? M2jCV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK4OFU2Lz5{NUGyPFQ2PTxxYU6=
EFM192A NHrnZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG1NFAhdk1? M{PreVEx6oDVMUZCpIQ> Mni0doVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> MoTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMki0OVUoRjJ3MUK4OFU2RC:jPh?=
MDA-MB-231 MYHGeY5kfGmxbjDBd5NigQ>? MWqxNE8zOC92MDFOwG0> NUDKfYZVOjRiaB?= NVvXOYpscW6lcnXhd4V{KHBvQVvUJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{MEG1Nkc,OjR2MkCxOVI9N2F-
MDA-MB-231 NXOwOIhjS2WubDDWbYFjcWyrdImgRZN{[Xl? M4Da[lAvOS12MDFOwG0> MVyyOEBp MXjJR|Ux6oDLPfMAjVE4Njd5wrFOwG0> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{MEG1Nkc,OjR2MkCxOVI9N2F-
MDA-MB-231 MoewRZBweHSxc3nzJGF{e2G7 MXOxNE8zOC92MDFOwG0> NE\DWXczPCCq NHnWTVBqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NE\Kc4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyNFE2Oid-MkS0NlAyPTJ:L3G+
MDA-MB-231 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjkWol[OTBxMkCvOFAh|ryP M1u0UlI1KGh? Mn3JZoxw[2u|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hcW5iR{KvUUBxcGG|ZR?= Mlq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkCxOVIoRjJ2NEKwNVUzRC:jPh?=
H460 Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzMT3c3PDByIH7N NWe1NFhJOjUEoHi= MYjpcoNz\WG|ZYOgZ4VtdHWuYYKgdoFlcW:|ZX7zbZRqfmm2eR?= NWjTUnY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVE3OTFpPkK0OFEyPjFzPD;hQi=>
A549  MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnydZM1ODBibl2= Mor3NlTDqGh? NITWVI9qdmO{ZXHz[ZMh[2WubIXsZZIhemGmaX;z[Y5{cXSrdnn0fS=> MnrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUG2NVEoRjJ2NEGxOlEyRC:jPh?=
DT40 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XUSWlEPTB;MkGgcm0> M{LWdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W2PFE{Lz5{NEO1OlgyOzxxYU6=
DU145 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjHVZhnUUN3ME2xPEBvVQ>? MkOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NU[4NVMoRjJ2M{W2PFE{RC:jPh?=
COLO704 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:yN|hsUUN3ME2yMlUzKMLzIECuOlch|ryP NHPiPXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVMANAb NV3ZU2E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DxeGlEPTB;Mj61PEDDuSByLkO4JO69VQ>? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OV177 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrrXoZKSzVyPUKuO|ghyrFiMD63NUDPxE1? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OAW28 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNwNkGgxtEhOC5{ODFOwG0> M1ruUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OVSAHO NHPsZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LFSmlEPTB;Mz62OEDDuSByLkOzJO69VQ>? NFLO[I09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVKATE MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW0TWM2OD1|Lk[0JOKyKDFwN{mg{txO NITyZmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OVCAR3 NXTmO41IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;zfFBQUUN3ME2zMlc1KMLzIECuOFAh|ryP M2W4dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
PEO14 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwOESgxtEhOC55NjFOwG0> Ml73QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
A2780 M1TwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwOUSgxtEhOC5{NTFOwG0> MofnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVTOKO NFSwWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwMUSgxtEhOS53MzFOwG0> NVjFPJVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
KURAMOCHIb NHfQbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHLc4I6UUN3ME20MlM1KMLzIECuNlkh|ryP MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
TOV21G NHG0Z5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwMEegxtEhOS5|MDFOwG0> NYjme41LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OVISE NIHJNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfZR3RuUUN3ME21MlY5KMLzIECuNlMh|ryP M3fufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
KK NXi3dVV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXywPJBbUUN3ME22MlE2KMLzIEGuOFIh|ryP MonEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
RMUGS M3fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTdwMEOgxtEhOS56MzFOwG0> NWHud41ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
PEO6 M4fYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTdwME[gxtEhOC55NDFOwG0> MkLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
OVCA429 NHLyXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTqZY9QUUN3ME24MlI6KMLzIEGuOlQh|ryP M3\tWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV167 M1\EWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mxO2lEPTB;OD6zN{DDuSBzLkG4JO69VQ>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
RMG1 NVmwN|lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv3WWxQUUN3ME25MlMzKMLzIEKuN|Yh|ryP MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCAR5 NXTFeHpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHQSVlyUUN3ME25MlUxKMLzIEKuOVkh|ryP MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
EFO21 NWHKW3U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL6TWM2OD17LkmyJOKyKDFwOEeg{txO MofrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
ES2 NIPDRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G1TGlEPTB;MUCuNVIhyrFiMT6yN{DPxE1? NFTCOpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
Tyk-nu MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr4RnhKSzVyPUGwMlIxKMLzIEGuNVIh|ryP NELNdY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
CAOV3 MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDYTWM2OD1zMD6zO{DDuSByLki3JO69VQ>? NV\lTXpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OV207 NF3KXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPhZ2YzUUN3ME2xNk4zPyEEsTCwMlMzKM7:TR?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
HEY M2jubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn3TWM2OD1zMz6wNUDDuSByLke1JO69VQ>? NU\jUJA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
DOV13 M2LFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRjF3IN88US=> MmnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
EFO27 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\xTWM2OD5zNTFOwG0> NFrtZ|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
HEY C2 NVrXNo11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRjF3IN88US=> M{e2[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
KOC-7cc MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrFTWM2OD5zNTFOwG0> M1vndFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
MCASb NEnPN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\2emlEPTB-MUWg{txO NYroW49URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OAW42 NHS3RVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvZb3NKSzVyPkG1JO69VQ>? M3TmS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K5OFAzLz5{M{eyPVQxOjxxYU6=
OV2008 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHQSYdKSzVyPkG1JO69VQ>? NE\6XmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
OV90 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvnWG9KSzVyPkG1JO69VQ>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
OVCA420b MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRjF3IN88US=> NWnoS2tHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
OVCA432 NHv6e2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SzcmlEPTB-MUWg{txO MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{OUSwNkc,OjN5Mkm0NFI9N2F-
PEA2 NUj5PYhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP0N|kyUUN3ME6xOUDPxE1? Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mkm0NFIoRjJ|N{K5OFAzRC:jPh?=
SKOV3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6zO481UUN3ME6xOUDPxE1? NFy1WFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOid-MkO3Nlk1ODJ:L3G+
TOV112D M2PYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS4NE0{KM7:TR?= NIq3b|RKSzVyPkG1JO69VQ>? NWrRRnVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3Nlk1ODJpPkKzO|I6PDB{PD;hQi=>
C4-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLhPZYxNTNizszN MXuxOEBl NH\DXmdFVVOR M3jqNIRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? M4KyNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
PC3 M1fSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHhNE0{KM7:TR?= MUWxOEBl MmXiSG1UVw>? M2PPPIRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? NX7GT2VORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1OlUzPDRpPkKzOVY2OjR2PD;hQi=>
DU145 NXTwZXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLiNE0{KM7:TR?= MXuxOEBl M{jpXWROW09? MVrk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 M3f4eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NU[1NlQ1Lz5{M{W2OVI1PDxxYU6=
VCaP  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\lWIFNOC1|IN88US=> NVnseHN1OTRiZB?= NYXmcJU6TE2VTx?= Mkni[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4NUK0OEc,OjN3NkWyOFQ9N2F-
LNCaP  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGwMVMh|ryP NUXBRoxwOTRiZB?= NW\IdmZ{TE2VTx?= MmTX[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? NGnDNZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2OVI1PCd-MkO1OlUzPDR:L3G+
MDA-MB-468 NYLMTXZnS2WubDDWbYFjcWyrdImgRZN{[Xl? MWfJR|UxRTlwNzFOwG0> NETEdJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O|gyPjF:L3G+
MDA-MB-231 MnfRR4VtdCCYaXHibYxqfHliQYPzZZk> MojuTWM2OD1zMzFOwG0> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ5OEG2NUc,OjJ4N{ixOlE9N2F-
Cal-51 M4PORWNmdGxiVnnhZoltcXS7IFHzd4F6 NFHPTWJKSzVyPUiuOkDPxE1? NHXtVVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[3PFE3OSd-MkK2O|gyPjF:L3G+
LoVo NW\vUoFbTnWwY4Tpc44h[XO|YYm= MUWzNEBucW6| MUnJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHWvYX6gUI9XdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJBwdHlqQVTQLU1zcWKxc3WgdI9tgW2ncnn6ZZRqd25iZn;yJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC5yMES2PUDPxE1w MnHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
MX1 NWTzOWtqS3m2b4TvfIlkcXS7IHHzd4F6 MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBDWkODMT3k[YZq[2mnboSgbJVu[W5iTWixJINmdGy|LDDFR|UxKD1iMD6wNFU{KM7:TT6= NEHNfHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
Rosetta2 (DE3) M1ixbGZ2dmO2aX;uJIF{e2G7 NWL4eYNPUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIE\4bIl{NXSjZ3fl[EBCWlSGNjCoPFc{KHSxIEGxOlEqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIGLvd4V1fGF{IDjESVMqKGOnbHzzJJV{cW6pIF7BSEsh[XNic4Xid5Rz[XSnIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODF2IN88UU4> M4DIelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO|cxLz5{NEmwNFc4ODxxYU6=
Rosetta2 (DE3) NX3TT|lUTnWwY4Tpc44h[XO|YYm= NGTzcWRKdmirYnn0bY9vKG:oIHj1cYFvKD[6aHnzMZRi\2enZDDBVnRFPSBqMUCzNEB1dyBzM{G3LUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCUb4PleJRiOiBqRFWzLUBk\WyuczD1d4lv\yCQQVSrJIF{KHO3YoP0doF1\SCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTBiPTCwMlAzPSEQvF2u MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe3NEc,OjR7MEC3O|A9N2F-
LoVo NVXnZ5JFS3m2b4TvfIlkcXS7IHHzd4F6 Ml21NE41KHWP M4jleVUh\GG7cx?= NEHSRZdRd3SnboTpZZRqd25ib3[geIVud3qxbH;tbYRmNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHnuJIh2dWGwIFzvWo8h[2WubIOgZZN{\XO|ZXSgZZMhfGWvb4rvcI9ucWSnIFfJOVAh[XRiMD60JJVOKGGodHXyJFUh\GG7czDifUBE\WyudHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5zNESg{txONg>? NYPMXnNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
Capan1 NGX1VGxEgXSxdH;4bYNqfHliYYPzZZk> M3Pi[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKUQ1GyMYRm\mmlaXXueEBpfW2jbjDDZZBidjFiY3XscJMtKEWFNUCgQUAxNjZyOTFOwG0v NHf0Rlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MDA-MB-436 MWHBcpRq[2GwY3XyJIF{e2G7 M1vlSlk3KGi{cx?= MlmxRY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLSR2EyNWSnZnnjbYVvfCCPRFGtUWIuPDN4IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEOFNUCgQUA{KM7:TT6= MnLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NEK4OlgoRjJ4M{SyPFY5RC:jPh?=
OVCAR3 M17xZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 Mly0NlQhcHK| NGPZeZdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;WR2FTOyClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gN{4{OSEQvF2u NIrVN289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1OlExPid-Mkm0OVYyODZ:L3G+
MRC5 NXnjN4NqS3m2b4TvfIlkcXS7IHHzd4F6 MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzMEBGSzVyIE2gPE42OyEQvF2u NHrpfo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NlcyPyd-Mk[2OVI4OTd:L3G+
MCF7 NX7QTmFvSW62aXPhcoNmeiCjc4PhfS=> M2PhdFk3KGi{cx?= M3;BdmFvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGNEPTBiPTCxPU41PyEQvF2u MmDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NEK4OlgoRjJ4M{SyPFY5RC:jPh?=
A673 NHv2e3JyUFSVIHHzd4F6 MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 M1XyOJFJXFNiYYPzZZk> MnjUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> M4HRflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NEHDOItyUFSVIHHzd4F6 Ml7hdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> MlTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC MVXxTHRUKGG|c3H5 MmfGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>? NHXyUGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 M{HEXJFJXFNiYYPzZZk> NXW2OGd1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Assay
Methods Test Index PMID
Western blot BRCA1 ; PAR 24085845 27960087
Growth inhibition assay Cell viability 31119062
Immunofluorescence 53BP1 ; γH2AX ; PAR ; α-tubulin 23565244 27515310 30589644
In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

Protocol (from reference)

Kinase Assay:[1]
  • Ki Determination:

    Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.

Cell Research:[4]
  • Cell lines: D425Med, D283Med and D384Med cells
  • Concentrations: 0.4 μM
  • Incubation Time: 3 or 5 days
  • Method: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
Animal Research:[4]
  • Animal Models: CD-1 nude mice bearing established D283Med xenografts
  • Dosages: 1 mg/kg
  • Administration: One or four daily by i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

10mg/mL

Chemical Information

Molecular Weight 421.36
Formula

C19H18FN3O.H3PO4

CAS No. 459868-92-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04539327 Recruiting Drug: Rucaparib Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Grupo Español de Investigación en Cáncer de Ovario|Clovis Oncology Inc. July 29 2020 --
NCT04179396 Active not recruiting Drug: Rucaparib|Drug: Enzalutamide|Drug: Abiraterone Metastatic Castration Resistant Prostate Cancer Clovis Oncology Inc. December 5 2019 Phase 1
NCT04171700 Recruiting Drug: Rucaparib Solid Tumor Clovis Oncology Inc. November 21 2019 Phase 2
NCT03824704 Terminated Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine August 23 2019 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy AG-014699|AG-014699 ic50|AG-014699 price|AG-014699 cost|AG-014699 solubility dmso|AG-014699 purchase|AG-014699 manufacturer|AG-014699 research buy|AG-014699 order|AG-014699 mouse|AG-014699 chemical structure|AG-014699 mw|AG-014699 molecular weight|AG-014699 datasheet|AG-014699 supplier|AG-014699 in vitro|AG-014699 cell line|AG-014699 concentration|AG-014699 nmr|AG-014699 in vivo|AG-014699 clinical trial|AG-014699 inhibitor|AG-014699 DNA Damage inhibitor